Biomarin Pharmaceutical (BMRN) FCF Margin (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly FCF Margin came in at 26.07% in Q1 2026, up 491.0% YoY from 4.41% in Q1 2025, and up 286.91% on a QoQ basis from 6.74% in Q4 2025.
Biomarin Pharmaceutical (BMRN) FCF Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of FCF Margin data on file, last reported at 26.07% in Q1 2026.
- Quarterly FCF Margin rose 491.0% year-over-year to 26.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.66% (up 250.0% YoY) and the FY2025 annual result came in at 22.51%, up 543.0% from the prior year.
- FCF Margin grew to 26.07% in Q1 2026, from 6.74% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 41.21% in Q3 2025 to a low of 23.5% in Q4 2022.
- A 5-year average of 12.77% and a median of 14.93% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin slumped 3240 bps — and 2023, when it surged 3342 bps.
- Tracing BMRN's FCF Margin over 5 years: stood at 23.5% in 2022, then soared by 142 bps to 9.92% in 2023, then surged by 124 bps to 22.23% in 2024, then plunged by 70 bps to 6.74% in 2025, then surged by 287 bps to 26.07% in 2026.
- The last three FCF Margin figures came in at 26.07% (Q1 2026), 6.74% (Q4 2025), and 41.21% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 14.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.07% |
| Mar 31, 2026 | 26.07% |
| Dec 31, 2025 | 6.74% |
| Sep 30, 2025 | 41.21% |
| Jun 30, 2025 | 22.84% |
| Mar 31, 2025 | 21.15% |
| Dec 31, 2024 | 22.23% |
| Sep 30, 2024 | 27.22% |
| Jun 30, 2024 | 13.68% |
| Mar 31, 2024 | 3.22% |
| Dec 31, 2023 | 9.92% |
| Sep 30, 2023 | 12.64% |
| Jun 30, 2023 | 14.93% |
| Mar 31, 2023 | -16.50% |
| Dec 31, 2022 | -23.50% |
| Sep 30, 2022 | 31.92% |
| Jun 30, 2022 | 17.65% |
| Mar 31, 2022 | -14.30% |
| Dec 31, 2021 | 1.11% |
| Sep 30, 2021 | 23.57% |